Is there a specific metabolic signature of breast cancer in blood?
In partnership between Prof. Ismael Dale,, Dept. of Gynecology, Federal University of Sao Paulo, and BIOCRATES novel metabolic blood biomarkers have been discovered. They could potentially be used for low-invasive diagnosis and prognostic evaluation of breast cancers have been discovered using the Biocrates AbsoluteIDQ® p180 Kit. Based on cancer specific metabolic changes, Prof. Dale and BIOCRATES identified individual blood metabolic signatures (=biomarkers) that could help for screening and/ or diagnosing breast cancer, identification of intrinsic subtypes, assessment of tumor activity as well as treatment response to neoadjuvant chemotherapy. It has been achieved to provide biomarkers signatures by measuring the individual concentrations and/or ratios of certain metabolites in blood samples. The biomarkers of the study make it possible to predict whether a patient is likely to reach complete pathological response (pCR) to neoadjuvant chemotherapy or stable disease and/or progression (SDPR). Further, it has been found out that intrinsic subtypes of breast cancer tumors can be distinguished on the basis of their specific metabolic signatures. In fact, the quantitative measurement of the endogenous metabolites contained in the respective sets of biomarkers allows a more sensitive and selective, and therefore more reliable assessment of breast cancer. The findings of the study have been presented at the recentBiomarker Conference in Munich.
MetIDQ™ Version 5 Boron Key Features:
• Dynamic pathway visualisation package (MetPATH) • Import parameters from Analyst®, MultiQuant™, Xcalibur™, MassLynx™ • Direct and improved export to MetaboAnalyst, SPSS, XLSX, CSV, XML … • Improved project and export format (DMP) for large projects Download MetIDQ Boron Factsheet
New Software Release: Now Available!
MetIDQ™ highly automates the whole FIA-MS/MS and LC-MS/MS process from project and sample administration to plate layout and worklist generation, technical validation and statistical analysis to standardize metabolomics project data processing. MetIDQ is an integral part of all AbsoluteIDQ® Kits. Watch MetIDQ Video from the ASMS 2014
T. D. Blydt-Hansen et al., American Journal of Transplantation 2014; 14(10): 1–11
NEW PUBLICATION Transplantation Medicine
Invasive methods for diagnosis are risky and unpleasant for patients. By using the Biocrates AbsoluteIDQ p180 Kit, Blydt-Hansen et al. could show that urinary metabolomics has great potential to become an important tool for the noninvasive diagnosis of T cell mediated rejection in pediatric kidney transplant recipients. Abstract More Publications
S. Baumann et al., 2014, JOURNAL OF INTEGRATED OMICS
NEW PUBLICATION Metabolomics & Cell Signaling
Connecting biochemical pathways with receptor induced intracellular kinase signaling is a great challenge in molecular medicine. Baumann et al. could show that changes in the metabolome affect kinase signaling. Here, the Biocrates AbsoluteIDQ p180 Kit enables reliable and reproducible data analysis to support and improve cell signaling research. Abstract More Publications
Biocrates Life Sciences AG, internationally renowned developer of targeted metabolic phenotyping solutions, supports the discovery and validation of biomarkers for complex multifactorial diseases in pre-clinical and clinical research.
BIOCRATES Life Sciences AG Eduard-Bodem-Gasse 8, 6020 Innsbruck
If you no longer wish to receive the BIOCRATES Life Sciences AG email newsletter, please click here to unsubscribe. This email was sent by: BIOCRATES Life Sciences AG, Eduard-Bodem-Gasse 8, 6020 Innsbruck firstname.lastname@example.org Phone +43.512.579 823, Fax +43.512.579 823–329, FN 220414 p LG Innsbruck, UID No.: ATU 56725128